Alexandre Harari

Alexandre Harari is an Associate Professor at the Department of Oncology, Faculty of Biology and Medicine, University of Lausanne (UNIL), affiliated with CHUV. He has been in this role since January 1, 2023, and has been a key figure in tumor immunology research and immuno-monitoring at UNIL-CHUV since 2010. He leads a research team at Hi-TIDe (Human Integrated Tumor Immunology Discovery Engine), a Ludwig Institute branch in Lausanne, and has held leadership positions including Head of the Immuno-Monitoring Unit and Deputy Scientific Director at the Center for Experimental Therapies.

• Institution: University of Lausanne (UNIL)
• Faculty: Faculty of Biology and Medicine
• Department: Department of Oncology
• Leadership Roles: Team Leader at Hi-TIDe, former Head of Immuno-Monitoring Unit, former Deputy Scientific Director

Alexandre Harari is an expert in cellular immunology, focusing on the dynamics between cellular immune responses and tumors. His research aims to define the optimal characteristics of antitumor immune cells in clinical settings, particularly in patients undergoing cell therapies or experimental vaccines. His work bridges basic immunology and translational oncology, with a strong emphasis on improving existing immunotherapies and developing novel ones. He has contributed extensively to understanding immune responses in both cancer and infectious diseases, having started his career in HIV immunopathogenesis.

Although no specific publications are listed in the provided text, Professor Harari has published as first or last author in top-tier journals such as Nature Medicine, Nature Biotechnology, Nature Cancer, Nature Communications, Nature Reviews Immunology, and Nature Reviews Drug Discovery, indicating a strong and influential research output in immunology and oncology. His work spans tumor immunobiology, immune monitoring technologies, and therapeutic development, reflecting a consistent trajectory in advancing cancer immunotherapy.

His scientific contributions have been recognized through several prestigious awards:

• Bristol-Myers Squibb (BMS) HIV & Research Award (2009)
• Young/Early Career Investigator Award from the Bill & Melinda Gates Foundation (2010)
• SwissTB Award (2012)
• Viollier Prize (2012)
• Prof. Dr. Max Cloëtta scholarship (2013, declined)

Professor Harari has played a significant role in mentoring and research leadership, having supervised research units and led large-scale experimental therapy programs. Although no formal advisees are listed, his leadership of research teams and units implies active supervision of junior scientists and doctoral candidates. He has not received external teaching awards, but his long-standing academic appointment and leadership roles underscore his contributions to training and academic development.

He leads a research team at Hi-TIDe (Human Integrated Tumor Immunology Discovery Engine), a branch of the Ludwig Institute for Cancer Research in Lausanne, which focuses on discovering and validating T cell responses in cancer. He has also directed the Immuno-Monitoring Unit at the Center for Experimental Therapies, Department of Oncology, UNIL-CHUV, contributing to the evaluation of immune responses in clinical trials.